CoChat

TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC)

Roy S. Herbst, Diane Prager, R. Hermann, V.A. Miller, Louis Fehrenbacher, P C Hoffman, Bruce Evan Johnson, Alan Sandler, ROBERT D. MASS, David H. Johnson · 2004 · Journal of Clinical Oncology
Cited by 146

The DOI matches its OpenAlex record.

Abstract

7011 Background: Tarceva™ (erlotinib) is a potent reversible HER1/EGFR tyrosine kinase inhibitor with single-agent antitumor activity. TRIBUTE was a prospective, placebo-controlled study randomizing patients (pts) with previously untreated advanced (Stage IIIB / IV) NSCLC to receive erlotinib at 150 mg/d or placebo (PBO) with a course of 6 cycles of CP followed by maintenance monotherapy. Methods: Pts with performance status (PS) of 0 or 1 were eligible. Randomization was stratified by stage, >5% weight loss prior 6 months, measurable disease, and study site. The primary endpoint was overall survival (OS). Secondary endpoints included time to progression (TTP), objective response (OR), duration of response and time to symptomatic progression (TTSP; as determined by the Lung Cancer Symptom Scale). Sample size of 1050 was based on 80% power to detect a 25% benefit in OS, α=0.05. Results: 1059 pts were randomized / treated (526 erlotinib; 533 PBO). As shown in the table below, there was no difference in median OS for patients treated with erlotinib with CP over CP alone, and no difference in OR or in median TTP. TTSP results to be presented. PBO and erlotinib were equivalent in terms of overall adverse (99.5% erlotinib, 99.5% PBO) and serious adverse events (excepting rash and diarrhea; 47.7% erlotinib, 43.2% PBO). There was an imbalance in the SAEs attributed by the reporting investigator as leading to death (53 erlotinib; 27 PBO). Only 5 of the 80 fatal SAEs were partially related to study drug (i.e., causality was also related to concurrent therapy or underlying condition) by the reporting investigators. Conclusions: Erlotinib combined with carboplatin and paclitaxel chemotherapy did not confer a survival advantage over carboplatin and paclitaxel alone in pts with previously untreated advanced NSCLC. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech Genentech Genentech AstraZeneca; Genentech Genentech

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

OpenAlex · 10.1200/jco.2004.22.14_suppl.7011

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 146

Metadata

Authors
Herbst, R. S., Prager, D., Hermann, R., Miller, V. A., Fehrenbacher, L., Hoffman, P. C., Johnson, B. E., Sandler, A., MASS, R. D., & Johnson, D. H.
Venue
Journal of Clinical Oncology
Publisher
Lippincott Williams & Wilkins
Published
2004-07-15
Volume
22
Issue
14_suppl
Pages
7011-7011
ISSN
0732-183X (ISSN-L)
OpenAlex
W2297901492
Cited by
146
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). https://app.cochat.ai/papers/10.1200/jco.2004.22.14_suppl.7011
The paper
Herbst, R. S., Prager, D., Hermann, R., Miller, V. A., Fehrenbacher, L., Hoffman, P. C., Johnson, B. E., Sandler, A., MASS, R. D., & Johnson, D. H. (2004). TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2004.22.14_suppl.7011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.